Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

a alpha 1 High-throughput screening cell model of -AR subtype selective antagonist and its construction method and application

A cell model, 1-AR technology, applied to cells modified by introducing foreign genetic material, biochemical equipment and methods, recombinant DNA technology, etc., can solve the problem of poor screening effect of anti-benign prostatic hyperplasia drugs, etc. To achieve the effect of efficient, fast and rapid screening of the method

Inactive Publication Date: 2016-08-24
GUANGZHOU MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a high-throughput screening method for screening anti-benign prostatic hyperplasia drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • a alpha <sub>1</sub> High-throughput screening cell model of -AR subtype selective antagonist and its construction method and application
  • a alpha <sub>1</sub> High-throughput screening cell model of -AR subtype selective antagonist and its construction method and application
  • a alpha <sub>1</sub> High-throughput screening cell model of -AR subtype selective antagonist and its construction method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] alpha 1 -Building process of high-throughput screening model for AR subtype-selective antagonists

[0038] S1. Preservation and extraction of plasmids (pGL4.29[luc2P / CRE / Hygro], pGL4.74[hRluc / TK], EX-A0967-M29, EX-Y3321-M29, EX-Y2008-M29).

[0039] S11. Plasmid transformation and storage: Transfer 1 µL of the above plasmid to the bottom of a 1.5 mL centrifuge tube for ice bath, add to 200 µL of competent cells (DH5α), mix well, and place in ice bath for 30 min. Heat shock at 42°C for 40s and ice bath for 3min. Add 400µL of S.O.C medium, shake and culture at 37°C for 1 hour, take 50µL and spread it on the surface of the solid medium plate containing 100ug / mL ampicillin. Cultivate overnight at 37°C, pick a single clone and inoculate it into 500 µL LB liquid medium, culture on a shaker at 37°C for 6 hours, add resistant glycerol containing 100 µg / mL ampicillin, and the final concentration of glycerol is 15-25%.

[0040] S12. Strain cultivation and plasmid extraction: Ad...

Embodiment 2

[0059] In order to determine the suitable reporter gene in the screening method of the present invention, the present invention studies the response of five response factors directly or indirectly related to α1-ARs, the specific method is as follows:

[0060] Will α 1 -ARs (ADRA1A, ADRA1B and ADRA1D) were co-transfected with the reporter gene and the internal reference plasmid (hRluc-TK) respectively. Negative control and blank control were used for drug addition to investigate the fluorescence induced by the reporter gene to phenylephrine in the co-transfection system. The influence of signal ratio, in which the reporter gene selects 5 main response elements that are directly or indirectly related to α1-ARs: ​​cyclic adenosinase response element (CRE), serum response element (SRE) and activin-1 response element ( AP-1), nuclear factor-кB (NF-кB-RE) and nuclear factor of activated T cells (NFAT-RE), respectively inserted into the firefly luciferase vector (luc2P) to construct....

Embodiment 3

[0061] Example 3 Scale Selection of Reporting Components

[0062] The difference in the ratio of the reporter element plasmid has an important influence on the difference in luciferase expression value caused by receptor signal transduction after adding phenylephrine stimulation. In order to ensure the stable and optimal expression of luciferase on the screening platform, the ratio of ADRA1D, reporter gene Luc2P-CRE, and internal reference plasmid (hRluc-TK) was optimized, other conditions and methods were fixed, and the ratio of reporter gene and internal reference plasmid was changed. , to detect differences in luciferase expression intensity at different doses. Such as figure 2 As shown, the eukaryotic expression plasmid, reporter gene, and internal reference plasmid are respectively 1:1:1; 1:10:1; 1:50:1; 1:100:1; 10:100:1; 50:100:1 ; 100:100:1 for co-transfection, the results showed ( figure 2 ), according to the plasmid ratio of 1:1:1, a better signal-to-noise ratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention specifically discloses a 1 ‑High-throughput screening cell model of AR subtype-selective antagonists and its construction method and application. The construction method is to use α 1 ‑AR three subtypes (α 1A ,α 1B ,α 1D ) eukaryotic expression plasmid, reporter gene and internal reference plasmid were co-transfected into host cells, and a transient cell model was established. Antagonists and agonists to be screened were added to the cell model successively. After a period of co-culture, the cells were lysed and the lysates were processed. Assay of luciferase activity, determine the relative expression of reporter gene and internal control, so as to evaluate the effect of the drug on α 1 ‑AR three subtypes: α 1A 、α 1B and alpha 1D inhibitory activity. This method passes model stability, volatility inspection and model verification. available for alpha 1 ‑High-throughput screening of AR subtype-selective antagonists can be further used to screen potential drugs for the treatment of benign prostatic hyperplasia.

Description

technical field [0001] The invention relates to the technical field of constructing cell models for high-throughput screening of drugs, in particular to an α 1 -High-throughput screening cell model of AR subtype-selective antagonists and its construction method and application. Background technique [0002] alpha 1 - Adrenoceptor (AR) can be divided into three subtypes according to clonotype (α 1A , α 1B and alpha 1D ), are widely distributed in vascular and nonvascular tissues, and regulate most of the physiological function responses of humans separately or jointly. With different adjustment functions. alpha 1A Regulate smooth muscle contraction, control urination, and control blood pressure; α 1D -AR is associated with aortic and coronary vasoconstriction; in recent years, α 1A Found to be the major dynamic factor causing bladder outlet block, antagonizing alpha 1A Can relieve urinary tract obstruction, and antagonize α 1D -AR can improve lower urinary tract sym...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/85C12N5/10C12Q1/02
Inventor 袁牧许芳黎枭徐静仪朱着何雪兰朱柳陈洪黄碧云
Owner GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com